Inspire Medical Systems Unveils Positive Data for Inspire V

Inspire Medical Systems ( (INSP) ) has provided an update.

In October 2025, Inspire Medical Systems published clinical outcomes data for their Inspire V system at the ISSS/AAO-HNS meetings in Indianapolis. The data, from a Singapore study and a limited U.S. market release, showed significant improvements in patient adherence, safety, and surgical efficiency compared to previous models. The Inspire V system demonstrated a 20% reduction in surgical times and superior respiratory sensing, leading to enhanced patient comfort and therapy outcomes. The results indicate a promising advancement in treating obstructive sleep apnea, with implications for increased adoption and potential changes in reimbursement levels.

The most recent analyst rating on (INSP) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.

Spark’s Take on INSP Stock

According to Spark, TipRanks’ AI Analyst, INSP is a Neutral.

The overall stock score is primarily influenced by strong financial performance and positive corporate events. However, technical analysis indicates bearish trends, and valuation concerns due to a high P/E ratio weigh down the score. Mixed earnings call sentiment also impacts the overall assessment.

To see Spark’s full report on INSP stock, click here.

More about Inspire Medical Systems

Inspire Medical Systems is a medical technology company that develops and commercializes innovative, minimally invasive solutions for patients with obstructive sleep apnea. Their proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.

Average Trading Volume: 1,151,892

Technical Sentiment Signal: Sell

Current Market Cap: $2.32B

Find detailed analytics on INSP stock on TipRanks’ Stock Analysis page.